Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileTracy Todd Batchelor, M.D.

TitleGiovanni Armenise - Harvard Professor of Neurology
InstitutionMassachusetts General Hospital
DepartmentNeurology
AddressMassachusetts General Hospital
Neuro-Oncology; Yawkey 9E
55 Fruit St
Boston MA 02114
Phone617/724-8770
Fax617/724-8769
vCardDownload vCard (login for email)

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
P50CA165962     (BATCHELOR, TRACY T)Sep 19, 2013 - Jul 31, 2018
NIH/NCI
SPORE: Targeted Therapies for Glioma
Role: Principal Investigator

R01CA129371     (BATCHELOR, TRACY T)Sep 1, 2007 - Mar 31, 2018
NIH/NCI
Angiogenesis-targeting therapy for glioblastoma
Role: Principal Investigator

K24CA125440     (BATCHELOR, TRACY T)Aug 1, 2007 - Jul 31, 2017
NIH/NCI
Clinical and Molecular Studies of Malignant Brain Tumors
Role: Principal Investigator

R13CA124293     (BATCHELOR, TRACY T)Sep 1, 2006 - Nov 30, 2017
NIH/NCI
Annual International Primary CNS Lymphoma Collaborative Group Meeting
Role: Principal Investigator

R21CA117079     (BATCHELOR, TRACY T)Sep 19, 2005 - Aug 31, 2008
NIH/NCI
A Phase 2 study of AZD2171 in Recurrent Glioblastoma
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Teng J, Carla da Hora C, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro Oncol. 2017 Jun 01; 19(6):820-832. PMID: 28062830.
    View in: PubMed
  2. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12. PMID: 28562358.
    View in: PubMed
  3. DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, Batchelor TT, Chen YB. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017 Apr 03. PMID: 28369839.
    View in: PubMed
  4. Wang N, Jain RK, Batchelor TT. New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics. 2017 Apr; 14(2):321-332. PMID: 28083806.
    View in: PubMed
  5. Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT, Cahill DP, Barker FG, Brastianos PK, Santagata S. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 Apr 01; 19(4):535-545. PMID: 28170043.
    View in: PubMed
  6. Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 Apr 01; 19(4):567-575. PMID: 27663390.
    View in: PubMed
  7. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Mar; 132(1):181-188. PMID: 28116649.
    View in: PubMed
  8. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 2017 Jan; 133(1):1-3. PMID: 27909809.
    View in: PubMed
  9. Yáñez ML, Miller JJ, Batchelor TT. Diagnosis and treatment of epidural metastases. Cancer. 2017 Apr 01; 123(7):1106-1114. PMID: 28026861.
    View in: PubMed
  10. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol. 2016 Dec 20. PMID: 27997995.
    View in: PubMed
  11. Batchelor TT. Primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):379-385. PMID: 27913504.
    View in: PubMed
  12. Giulino-Roth L, Abla O, Batchelor TT. Management of primary central nervous system lymphoma in children. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):386-389. PMID: 27913505.
    View in: PubMed
  13. Hansen MB, Tietze A, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Østergaard L, Mouridsen K. Reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2016 Nov 30. PMID: 27902858.
    View in: PubMed
  14. Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017 Jan 20; 35(3):361-369. PMID: 27893327.
    View in: PubMed
  15. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 Feb; 131(3):603-610. PMID: 27853960.
    View in: PubMed
  16. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model. IEEE Trans Med Imaging. 2016 Nov 08. PMID: 27845656.
    View in: PubMed
  17. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model. IEEE Trans Med Imaging. 2017 Mar; 36(3):815-825. PMID: 28113925.
    View in: PubMed
  18. Boujelben A, Watson M, McDougall S, Yen YF, Gerstner ER, Catana C, Deisboeck T, Batchelor TT, Boas D, Rosen B, Kalpathy-Cramer J, Chaplain MA. Multimodality imaging and mathematical modelling of drug delivery to glioblastomas. Interface Focus. 2016 Oct 06; 6(5):20160039. PMID: 27708763.
    View in: PubMed
  19. Ohnishi T, Nakamura Y, Tanaka T, Tanaka T, Hashimoto N, Haneishi H, Batchelor TT, Gerstner ER, Taylor JW, Snuderl M, Yagi Y. Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract. 2016 Oct; 212(10):927-936. PMID: 27613662.
    View in: PubMed
  20. Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016 Nov; 18(11):1569-1578. PMID: 27382115.
    View in: PubMed
  21. Ho AL, Koch MJ, Tanaka S, Eichler AF, Batchelor TT, Tanboon J, Louis DN, Cahill DP, Chi AS, Curry WT. Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. J Clin Neurosci. 2016 Sep; 31:99-105. PMID: 27279154.
    View in: PubMed
  22. Chukwueke U, Batchelor T, Brastianos P. Management of Brain Metastases in Patients With Melanoma. J Oncol Pract. 2016 Jun; 12(6):536-42. PMID: 27288470.
    View in: PubMed
  23. Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016 Jul 07; 128(1):32-6. PMID: 27207798; PMCID: PMC4968379 [Available on 07/07/17].
  24. Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N. MRI Based Bayesian Personalization of a Tumor Growth Model. IEEE Trans Med Imaging. 2016 Oct; 35(10):2329-2339. PMID: 27164582.
    View in: PubMed
  25. Le M, Delingette H, Kalpathy-Cramer J, Gerstner E, Batchelor T, Unkelbach J, Ayache N. MRI Based Bayesian Personalization of a Tumor Growth Model. IEEE Trans Med Imaging. 2016 Apr 29. PMID: 28113549.
    View in: PubMed
  26. Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT, Flaherty KT, Onozato ML, Lelic N, Sundaram S, Cahill DP, Chi AS, Wakimoto H. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res. 2016 Sep 01; 22(17):4452-65. PMID: 27076630; PMCID: PMC5010492 [Available on 03/01/17].
  27. Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4470-5. PMID: 27044097; PMCID: PMC4843449.
  28. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4476-81. PMID: 27044098; PMCID: PMC4843473.
  29. Curry WT, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 Jun 15; 22(12):2885-96. PMID: 26873960; PMCID: PMC4911283 [Available on 06/15/17].
  30. Rapalino O, Batchelor T, González RG. Intra-axial brain tumors. Handb Clin Neurol. 2016; 135:253-74. PMID: 27432670.
    View in: PubMed
  31. Batchelor TT, Thye LS, Habermann TM. Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. Am Soc Clin Oncol Educ Book. 2016; 35:e354-66. PMID: 27249742.
    View in: PubMed
  32. Batchelor T, Rodon J, Ahluwalia M. Principles of pharmacotherapy. Handb Clin Neurol. 2016; 134:149-62. PMID: 26948353.
    View in: PubMed
  33. Sherman JC, Colvin MK, Mancuso SM, Batchelor TT, Oh KS, Loeffler JS, Yeap BY, Shih HA. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol. 2016 Jan; 126(1):157-64. PMID: 26498439.
    View in: PubMed
  34. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MV, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14; 28(6):773-84. PMID: 26678339; PMCID: PMC4684594 [Available on 12/14/16].
  35. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97. PMID: 26618888.
    View in: PubMed
  36. Nahed BV, Redjal N, Brat DJ, Chi AS, Oh K, Batchelor TT, Ryken TC, Kalkanis SN, Olson JJ. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015 Dec; 125(3):609-30. PMID: 26530264.
    View in: PubMed
  37. Andronesi OC, Loebel F, Bogner W, Marjanska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41. PMID: 26534967; PMCID: PMC4818725 [Available on 04/01/17].
  38. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-77. PMID: 26410082; PMCID: PMC4916970.
  39. Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J. Standard chemoradiation for glioblastoma results in progressive brain volume loss. Neurology. 2015 Aug 25; 85(8):683-91. PMID: 26208964; PMCID: PMC4553035 [Available on 08/25/16].
  40. Batchelor TT, Chen YB, Rapalino O, Cobos I. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 23-2015. A 51-Year-Old Woman with Headache, Cognitive Impairment, and Weakness. N Engl J Med. 2015 Jul 23; 373(4):367-77. PMID: 26200983.
    View in: PubMed
  41. Batchelor T. Managing primary central nervous system lymphoma. Clin Adv Hematol Oncol. 2015 Jul; 13(7):438-40. PMID: 26353039.
    View in: PubMed
  42. Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM. Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma. AJNR Am J Neuroradiol. 2015 Sep; 36(9):1654-61. PMID: 26066626; PMCID: PMC4567906 [Available on 09/01/16].
  43. Neagu MR, Gill CM, Batchelor TT, Brastianos PK. Genomic profiling of brain metastases: current knowledge and new frontiers. Chin Clin Oncol. 2015 Jun; 4(2):22. PMID: 26112808.
    View in: PubMed
  44. Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46. PMID: 26055170; PMCID: PMC4486737.
  45. Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92. PMID: 26008604; PMCID: PMC4578584 [Available on 10/01/16].
  46. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8. PMID: 25910950; PMCID: PMC4790106.
  47. Betensky RA, Szymonifka J, Lee EQ, Nutt CL, Batchelor TT. Computationally simple analysis of matched, outcome-based studies of ordinal disease states. Stat Med. 2015 Jul 30; 34(17):2514-27. PMID: 25900819; PMCID: PMC4490001.
  48. Nayak L, Pentsova E, Batchelor TT. Primary CNS lymphoma and neurologic complications of hematologic malignancies. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):355-72. PMID: 25837901.
    View in: PubMed
  49. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213. PMID: 25713439; PMCID: PMC4517055 [Available on 04/01/16].
  50. Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Ann Oncol. 2015 Jul; 26(7):1305-13. PMID: 25701456; PMCID: PMC4735103.
  51. Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, Winrich BK, Batchelor TT, Thornton LT, Mancuso SM, Saums MK, Oh KS, Curry WT, Loeffler JS, Yeap BY. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer. 2015 May 15; 121(10):1712-9. PMID: 25585890.
    View in: PubMed
  52. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7. PMID: 25572329; PMCID: PMC4483124 [Available on 06/01/16].
  53. Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun. 2014 Dec 24; 2:167. PMID: 25589003; PMCID: PMC4297409.
  54. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6. PMID: 25527270; PMCID: PMC4335993 [Available on 01/20/16].
  55. Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34. PMID: 25503302; PMCID: PMC4324090.
  56. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63. PMID: 25411098; PMCID: PMC4323868 [Available on 02/01/16].
  57. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9. PMID: 25398844; PMCID: PMC4234180.
  58. Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015 Jan 15; 121(2):226-33. PMID: 25204639; PMCID: PMC4293259.
  59. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309. PMID: 25139148; PMCID: PMC4221467.
  60. Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol. 2014 Oct; 11(10):566-84. PMID: 25113840; PMCID: PMC4445139.
  61. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21. PMID: 25100872; PMCID: PMC4483051 [Available on 01/01/16].
  62. Loebel F, Cahill DP, Bogner W, Marjanska M, Gerstner E, Batchelor T, Rosen BR, Chi AS, Andronesi OC. Sherry apple resident travel scholarship 194 assessment of treatment response in isocitrate dehydrogenase-mutant gliomas by quantification of 2-hydroxyglutarate with in vivo 3-dimensional magnetic resonance spectroscopy. Neurosurgery. 2014 Aug; 61 Suppl 1:224. PMID: 25032645.
    View in: PubMed
  63. Nahed BV, Sullivan JP, Madden MW, Oliveira SM, Chi AS, Springer S, Wakimoto H, Bhere D, Shah A, Spuhler P, Batchelor T, Louis DN, Toner M, Maheswaran S, Haber DA. American brain tumor association young investigator award 198 circulating tumor cells in patients with glioblastoma. Neurosurgery. 2014 Aug; 61 Suppl 1:226. PMID: 25032649.
    View in: PubMed
  64. Wen PY, Wen PY, Yung WK, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, Chi AS, Batchelor T, Chang SM, Prados MD, Reardon DA, Ligon KL. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47. PMID: 25165346.
    View in: PubMed
  65. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12. PMID: 25165209.
    View in: PubMed
  66. Batchelor TT, van den Bent MJ. Reply to M.C. Chamberlain. J Clin Oncol. 2014 Jul 20; 32(21):2273-4. PMID: 24934784.
    View in: PubMed
  67. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014 Jun 01; 20(11):2898-909. PMID: 24714777; PMCID: PMC4070445.
  68. Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist. 2014 Apr; 19(4):403-13. PMID: 24664484; PMCID: PMC3983820.
  69. Poynton CB, Chen KT, Chonde DB, Izquierdo-Garcia D, Gollub RL, Gerstner ER, Batchelor TT, Catana C. Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. Am J Nucl Med Mol Imaging. 2014; 4(2):160-71. PMID: 24753982; PMCID: PMC3992209.
  70. Batchelor TT. Comment: defining cure in primary CNS lymphoma. Neurology. 2014 Apr 15; 82(15):1373. PMID: 24634452.
    View in: PubMed
  71. Reuter M, Gerstner ER, Rapalino O, Batchelor TT, Rosen B, Fischl B. Impact of MRI head placement on glioma response assessment. J Neurooncol. 2014 May; 118(1):123-9. PMID: 24566765; PMCID: PMC4026260.
  72. Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81. PMID: 24309981; PMCID: PMC3903059.
  73. Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol. 2013 Dec; 14(4):539-52. PMID: 23934511; PMCID: PMC3841579.
  74. Ponzoni M, Issa S, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol. 2014 Feb; 25(2):316-22. PMID: 24265352; PMCID: PMC3905778.
  75. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64. PMID: 24190997; PMCID: PMC3839699.
  76. Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, Deangelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology. 2013 Nov 05; 81(19):1690-6. PMID: 24107866; PMCID: PMC3812109.
  77. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013 Sep; 123(9):3659-63. PMID: 23999439; PMCID: PMC3754248.
  78. Ferreri AJ, Zucca E, Armitage J, Cavalli F, Batchelor TT. Ten years of international primary CNS lymphoma collaborative group studies. J Clin Oncol. 2013 Sep 20; 31(27):3444-5. PMID: 23960177.
    View in: PubMed
  79. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83. PMID: 23955713; PMCID: PMC3769525.
  80. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10; 31(26):3212-8. PMID: 23940216; PMCID: PMC4021043.
  81. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87. PMID: 23828240; PMCID: PMC3714160.
  82. Batchelor TT. Flying solo: chemotherapy without radiation for primary CNS lymphoma. J Clin Oncol. 2013 Sep 01; 31(25):3051-3. PMID: 23715569.
    View in: PubMed
  83. Clark SW, Taylor J, Wang DL, Abramson JS, Batchelor TT. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology. 2013 Jul 02; 81(1):93-4. PMID: 23685934; PMCID: PMC3770207.
  84. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5. PMID: 23553268; PMCID: PMC3688016.
  85. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol. 2013 May 10; 31(14):e233-6. PMID: 23547069.
    View in: PubMed
  86. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1. PMID: 23565532.
    View in: PubMed
  87. de Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714460.
    View in: PubMed
  88. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. PMID: 23197589; PMCID: PMC3563362.
  89. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013 Jan; 10(1):14-26. PMID: 23183634.
    View in: PubMed
  90. Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012 Sep-Oct; 18(5):463-8. PMID: 23006953.
    View in: PubMed
  91. Brastianos PK, Batchelor TT. Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Oncol Clin North Am. 2012 Aug; 26(4):897-916. PMID: 22794289.
    View in: PubMed
  92. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98. PMID: 22821383; PMCID: PMC3583376.
  93. Batchelor TT, Sorensen AG, Louis DN. Case records of the Massachusetts General Hospital. Case 17-2012. A 54-year-old man with visual-field loss and a mass in the brain. N Engl J Med. 2012 May 31; 366(22):2112-20. PMID: 22646634.
    View in: PubMed
  94. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63. PMID: 22649140; PMCID: PMC3434985.
  95. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012 Nov 15; 118(22):5601-7. PMID: 22517399; PMCID: PMC3423527.
  96. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012 Jan 11; 4(116):116ra4. PMID: 22238332; PMCID: PMC3720836.
  97. Gerstner ER, Batchelor TT. Antiangiogenic therapy for glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):45-50. PMID: 22290257; PMCID: PMC3269655.
  98. Goldlust SA, Cavaliere R, Newton HB, Hsu M, Deangelis LM, Batchelor TT, Gilbert MR, Lassman AB. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol. 2012 Apr; 107(2):407-11. PMID: 22203237.
    View in: PubMed
  99. Chi AS, Batchelor TT, Kwak EL, Clark JW, Wang DL, Wilner KD, Louis DN, Iafrate AJ. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol. 2012 Jan 20; 30(3):e30-3. PMID: 22162573.
    View in: PubMed
  100. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7. PMID: 22127927; PMCID: PMC3261301.
  101. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011; 16(11):1589-99. PMID: 22045784; PMCID: PMC3233294.
  102. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8. PMID: 21984064.
    View in: PubMed
  103. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol. 2011 Dec; 13(12):1324-30. PMID: 21954442; PMCID: PMC3223097.
  104. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451; PMCID: PMC4836609.
  105. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Jan; 18(1):76-83. PMID: 21749848.
    View in: PubMed
  106. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011 Jun; 13(6):566-79. PMID: 21636705; PMCID: PMC3107100.
  107. Drappatz J, Raizer JJ, Schiff D, Chi AS, Batchelor T, Snodgrass SM, Quant EC, Norden AD, Beroukhim R, Grimm SA, Doherty LM, Ciampa AS, LaFrankie DC, Ruland S, Gerard M, Hammond S, Wen PY. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J Clin Oncol. 2011 May 20; 29(15_suppl):2050. PMID: 28019939.
    View in: PubMed
  108. Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040. PMID: 28023794.
    View in: PubMed
  109. De Groot JF, Cloughesy T, Lieberman FS, Chang SM, Omuro AM, Drappatz J, Batchelor T, DeAngelis LM, Gilbert MR, Yung WK, Fisher JD, Ye X, Lamborn K, Chen AP, Grossman SA, Prados M, Wen PY. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2043. PMID: 28023799.
    View in: PubMed
  110. Chi AS, Kwak EL, Clark JW, Wang DL, Louis DN, Iafrate AJ, Batchelor T. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2072. PMID: 28019895.
    View in: PubMed
  111. Quant EC, Batchelor T, Lassman AB, Schiff D, Kaley TJ, Wong E, Mikkelsen T, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, Sceppa C, Gerard M, Hallisey SD, Bochacki CA, Smith KH, Muzikansky A, Wen PY. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2069. PMID: 28019932.
    View in: PubMed
  112. Hammond S, Norden AD, Lesser GJ, Drappatz J, Fadul CE, Batchelor T, Quant EC, Beroukhim R, Muzikansky A, Ciampa AS, Doherty LM, LaFrankie DC, Ruland S, Bochacki CA, Griffin K, Gerard M, Sceppa C, Rosenfeld MR, Wen PY. Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2038. PMID: 28023831.
    View in: PubMed
  113. Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011; 9:Doc11. PMID: 21698087; PMCID: PMC3118693.
  114. Kim H, Catana C, Ratai EM, Andronesi OC, Jennings DL, Batchelor TT, Jain RK, Sorensen AG. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res. 2011 Jun 01; 71(11):3745-52. PMID: 21507932; PMCID: PMC3107375.
  115. Emblem KE, Bjornerud A, Mouridsen K, Borra RJ, Batchelor TT, Jain RK, Sorensen AG. T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab. 2011 Oct; 31(10):2054-64. PMID: 21505476; PMCID: PMC3208147.
  116. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948. PMID: 21479234; PMCID: PMC3066220.
  117. Illerhaus G, Batchelor T. PCNSL: biomarker better than biopsy? Blood. 2011 Mar 17; 117(11):2987-9. PMID: 21415274.
    View in: PubMed
  118. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 08; 76(10):929-30. PMID: 21383331; PMCID: PMC3059144.
  119. Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghesquieres H, Silver M, Betensky RA, Batchelor T. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011 Jan 15; 17(2):346-52. PMID: 21224370; PMCID: PMC4058714.
  120. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28. PMID: 21199795; PMCID: PMC3074948.
  121. Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62. PMID: 21149667.
    View in: PubMed
  122. Mohapatra G, Engler DA, Starbuck KD, Kim JC, Bernay DC, Scangas GA, Rousseau A, Batchelor TT, Betensky RA, Louis DN. Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. Acta Neuropathol. 2011 Apr; 121(4):529-43. PMID: 21080181; PMCID: PMC3059338.
  123. Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol. 2010 Nov; 22(6):598-603. PMID: 20689430.
    View in: PubMed
  124. Kahn J, Loeffler JS, Niemierko A, Chiocca EA, Batchelor T, Chakravarti A. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):232-8. PMID: 20947265.
    View in: PubMed
  125. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32. PMID: 20821342; PMCID: PMC4090923.
  126. Brastianos PK, Batchelor TT. Vascular endothelial growth factor inhibitors in malignant gliomas. Target Oncol. 2010 Sep; 5(3):167-74. PMID: 20821351.
    View in: PubMed
  127. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43. PMID: 20736812; PMCID: PMC4030413.
  128. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010 Oct; 12(10):1071-7. PMID: 20615924; PMCID: PMC3018929.
  129. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. PMID: 20458050; PMCID: PMC2903316.
  130. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol. 2010 Nov; 100(2):261-8. PMID: 20449631; PMCID: PMC3811044.
  131. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010 Jun 17; 115(24):5005-11. PMID: 20368468; PMCID: PMC3710441.
  132. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010 Mar; 67(3):291-7. PMID: 20212226.
    View in: PubMed
  133. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7. PMID: 20156808; PMCID: PMC2940643.
  134. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):85-90. PMID: 20137866.
    View in: PubMed
  135. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72. PMID: 20406897; PMCID: PMC2940624.
  136. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2010 Feb 20; 28(6):e91-3. PMID: 19933906.
    View in: PubMed
  137. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009 Nov 03; 73(18):1509-10. PMID: 19884580; PMCID: PMC2779003.
  138. Brastianos PK, Batchelor TT. VEGF inhibitors in brain tumors. Clin Adv Hematol Oncol. 2009 Nov; 7(11):753-60, 768. PMID: 20075834.
    View in: PubMed
  139. Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs. 2009 Oct; 18(10):1549-57. PMID: 19671039; PMCID: PMC2761074.
  140. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009 Sep 01; 27(25):4155-61. PMID: 19636006; PMCID: PMC2734427.
  141. Michaud DS, Holick CN, Batchelor TT, Giovannucci E, Hunter DJ. Prospective study of meat intake and dietary nitrates, nitrites, and nitrosamines and risk of adult glioma. Am J Clin Nutr. 2009 Sep; 90(3):570-7. PMID: 19587083; PMCID: PMC2728643.
  142. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 01; 69(13):5296-300. PMID: 19549889; PMCID: PMC2824172.
  143. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38. PMID: 19483739; PMCID: PMC3057433.
  144. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009 Jun; 14(6):621-36. PMID: 19487335; PMCID: PMC4790121.
  145. Rosenfeld MR, Chamberlain M, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18-month survival data (NABTT 0501). J Clin Oncol. 2009 May 20; 27(15_suppl):2002. PMID: 27964563.
    View in: PubMed
  146. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009 May 20; 27(15_suppl):2047. PMID: 27964644.
    View in: PubMed
  147. Supko JG, Grossman SA, Peereboom DM, Chowdhary S, Lesser GJ, Nabors LB, Mikkelsen T, Desideri S, Batchelor TT. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2039. PMID: 27964617.
    View in: PubMed
  148. Chi AS, Gerstner ER, Eichler AF, Chea HK, Drappatz J, Wen PY, Ivy SP, Loeffler JS, Sorensen AG, Jain RK, Batchelor TT. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010. PMID: 27962847.
    View in: PubMed
  149. Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035. PMID: 27964624.
    View in: PubMed
  150. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):e13023. PMID: 27962794.
    View in: PubMed
  151. Nabors LB, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S. NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2001. PMID: 27964566.
    View in: PubMed
  152. Quant EC, Silver M, Yip S, Ryg P, Provencher K, McCormack K, Louis DN, Betensky R, Nutt C, Batchelor TT. Case-control study of long-term survivors of glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13021. PMID: 27962816.
    View in: PubMed
  153. Aghi MK, Batchelor TT, Louis DN, Barker FG, Curry WT. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol. 2009 May; 93(1):115-20. PMID: 19430887.
    View in: PubMed
  154. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep. 2009 May; 9(3):254-62. PMID: 19348715; PMCID: PMC4790123.
  155. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36. PMID: 19333229; PMCID: PMC4793889.
  156. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009 May 20; 27(15):2542-52. PMID: 19332720; PMCID: PMC2739611.
  157. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 01; 113(1):266-7; author reply 267-8. PMID: 19122120; PMCID: PMC2614638.
  158. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep. 2009 Jan; 11(1):73-80. PMID: 19080745; PMCID: PMC4110181.
  159. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008 Dec; 21(6):728-35. PMID: 18989120.
    View in: PubMed
  160. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008 Oct 21; 71(17):1355-60. PMID: 18936428; PMCID: PMC4109164.
  161. Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009 Apr; 11(2):211-5. PMID: 18757775; PMCID: PMC2718993.
  162. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44. PMID: 18711427; PMCID: PMC4795821.
  163. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT. CNS Hodgkin lymphoma. Blood. 2008 Sep 01; 112(5):1658-61. PMID: 18591379; PMCID: PMC3710443.
  164. Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol. 2008 Aug; 10(4):608-16. PMID: 18577560; PMCID: PMC2666235.
  165. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):222-7. PMID: 18513880.
    View in: PubMed
  166. Grossman SA, Ye X, Chamberlain MC, Mikkelsen T, Batchelor TT, Desideri S, Piantadosi S, Fine HA. Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2014. PMID: 27948415.
    View in: PubMed
  167. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501). J Clin Oncol. 2008 May 20; 26(15_suppl):2055. PMID: 27948099.
    View in: PubMed
  168. di Tomaso E, Frosch MP, Auluck PK, Cahill D, Duda DG, Plotkin SR, Loeffler JS, Sorensen AG, Batchelor TT, Jain RK. Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009. PMID: 27948447.
    View in: PubMed
  169. Batchelor TT, Lesser GJ, Grossman SA. Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma. J Clin Oncol. 2008 May 20; 26(15_suppl):2043. PMID: 27948117.
    View in: PubMed
  170. Duda DG, Cohen KS, Ancukiewicz M, di Tomaso E, Zhu AX, Penson RT, Horowitz NS, Batchelor TT, Willett CG, Jain RK. A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents. J Clin Oncol. 2008 May 20; 26(15_suppl):3544. PMID: 27949773.
    View in: PubMed
  171. Plotkin SR, Halpin CF, McKenna MJ, Batchelor TT, Loeffler JS, Barker FG. Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib. J Clin Oncol. 2008 May 20; 26(15_suppl):2045. PMID: 27948119.
    View in: PubMed
  172. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8. PMID: 18403492; PMCID: PMC2563052.
  173. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53. PMID: 18352856; PMCID: PMC2871667.
  174. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008 Apr; 10(2):190-8. PMID: 18287342; PMCID: PMC2613821.
  175. Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008 May; 88(1):43-50. PMID: 18231723; PMCID: PMC2658810.
  176. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008 Jan 29; 70(5):401-2. PMID: 18227422; PMCID: PMC4118737.
  177. Cahill DP, Codd PJ, Batchelor TT, Curry WT, Louis DN. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg. 2008; 55:165-71. PMID: 19248684.
    View in: PubMed
  178. Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec; 16(12):1895-908. PMID: 18041999.
    View in: PubMed
  179. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008 Feb 01; 111(3):1085-93. PMID: 17962515.
    View in: PubMed
  180. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan; 86(2):211-5. PMID: 17896078.
    View in: PubMed
  181. Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007 Nov; 18(11):1851-5. PMID: 17804469.
    View in: PubMed
  182. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22. PMID: 17643088.
    View in: PubMed
  183. Drappatz J, Batchelor TT. Leptomeningeal neoplasms. Curr Treat Options Neurol. 2007 Jul; 9(4):283-93. PMID: 17580008.
    View in: PubMed
  184. Eichler AF, Batchelor TT, Henson JW. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro Oncol. 2007 Jul; 9(3):373-7. PMID: 17522329; PMCID: PMC1907407.
  185. Gerstner E, Batchelor T. Primary CNS lymphoma. Expert Rev Anticancer Ther. 2007 May; 7(5):689-700. PMID: 17492932.
    View in: PubMed
  186. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007 Jun; 13(6):223-30. PMID: 17462954; PMCID: PMC2686126.
  187. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007 Jul; 9(3):354-63. PMID: 17452651; PMCID: PMC1907419.
  188. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007 Apr 01; 13(7):2038-45. PMID: 17404084; PMCID: PMC2873832.
  189. Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie. 2007 Mar; 30(3):90-1. PMID: 17341892.
    View in: PubMed
  190. Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JE, Abrey LE, Batchelor TT, Schiff D. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007 Jul; 18(7):1145-51. PMID: 17284616.
    View in: PubMed
  191. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95. PMID: 17222792; PMCID: PMC2748664.
  192. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006 Dec; 20(6):1337-61. PMID: 17113467.
    View in: PubMed
  193. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 2006 Dec; 65(12):1181-8. PMID: 17146292.
    View in: PubMed
  194. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus. 2006 Nov 15; 21(5):E15. PMID: 17134117.
    View in: PubMed
  195. Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol. 2007 May; 59(6):817-23. PMID: 16972068.
    View in: PubMed
  196. Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 01; 12(17):5174-81. PMID: 16951236.
    View in: PubMed
  197. Kesari S, Schiff D, Doherty L, Gigas D, Batchelor T, Muzikansky A, O'Neill A, Drappatz J, Kieran M, Wen PY. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1569. PMID: 27952494.
    View in: PubMed
  198. Gerber DE, Ye X, Grossman SA, Batchelor T. Calculated versus measured creatinine clearance for the dosing of methotrexate in patients with primary CNS lymphoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1536. PMID: 27952287.
    View in: PubMed
  199. Glantz MJ, Chamberlain MC, Batchelor T, Eric W, Cavalli F, Shapiro WR. Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients wtih neoplastic meningitis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1530. PMID: 27952295.
    View in: PubMed
  200. Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Nancy D, Batchelor T, Abrey L. Primary intraocular lymphoma (PIOL): An International Primary CNS Lymphoma Collaborative group report. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1534. PMID: 27952289.
    View in: PubMed
  201. Issa S, Hwang J, Karch J, Fridlyand J, Prados M, Batchelor T, Aldape K, Haqq C, Damon L, Rubenstein J. Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7595. PMID: 27955383.
    View in: PubMed
  202. Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist. 2006 Jun; 11(6):681-93. PMID: 16794247.
    View in: PubMed
  203. Jahnke K, Korfel A, O'Neill BP, Blay JY, Abrey LE, Martus P, Poortmans PM, Shenkier TN, Batchelor TT, Neuwelt EA, Raizer JJ, Schiff D, Pels H, Herrlinger U, Stein H, Thiel E. International study on low-grade primary central nervous system lymphoma. Ann Neurol. 2006 May; 59(5):755-62. PMID: 16586496.
    View in: PubMed
  204. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006 Apr 15; 66(8):3987-91. PMID: 16618716.
    View in: PubMed
  205. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006 Mar 10; 24(8):1281-8. PMID: 16525183.
    View in: PubMed
  206. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 01; 107(9):3716-23. PMID: 16418334; PMCID: PMC1895776.
  207. Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006 Jan; 8(1):38-46. PMID: 16443946; PMCID: PMC1871928.
  208. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8600-5. PMID: 16361543.
    View in: PubMed
  209. Batchelor T. Neuro-oncology update: 2005. Curr Opin Neurol. 2005 Dec; 18(6):631. PMID: 16280672.
    View in: PubMed
  210. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol. 2005 Oct; 18(5):604-10. PMID: 16155448.
    View in: PubMed
  211. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005 Aug; 19(4):689-703, vii. PMID: 16083830.
    View in: PubMed
  212. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):704-10. PMID: 15978739.
    View in: PubMed
  213. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005 Aug 01; 23(22):5034-43. PMID: 15955902.
    View in: PubMed
  214. Lesser GJ, Grossman SA, Carson K, Phupanich S, Batchelor T, Peereboom D, Nabors LB, Supko J, Hausheer F. Phase I study of karenitecin in the treatment of recurrent malignant gliomas (MG). J Clin Oncol. 2005 Jun; 23(16_suppl):1527. PMID: 27947141.
    View in: PubMed
  215. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Does phenytoin does affect celecoxib pharmacokinetics in patients with newly diagnosed glioblastoma multiforme? J Clin Oncol. 2005 Jun; 23(16_suppl):2085. PMID: 27946645.
    View in: PubMed
  216. Peerebom D, Batchelor T, Lesser G, Phuphanich S, Mikkelsen T, Carson K, Desideri S, Fisher J, Grossman S. NABTT 2111: A phase I trial of BMS-247550 for patients with recurrent high-grade gliomas. J Clin Oncol. 2005 Jun; 23(16_suppl):1563. PMID: 27946962.
    View in: PubMed
  217. Betensky RA, Nutt CL, Batchelor TT, Louis DN. Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers. J Mol Diagn. 2005 May; 7(2):276-82. PMID: 15858152; PMCID: PMC1867516.
  218. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005 Apr 01; 23(10):2233-9. PMID: 15800313.
    View in: PubMed
  219. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res. 2005 Mar 15; 11(6):2258-64. PMID: 15788675.
    View in: PubMed
  220. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005 Mar 01; 23(7):1507-13. PMID: 15735126.
    View in: PubMed
  221. Batchelor TT, Buchbinder BR, Harris NL. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, headache, and nausea. N Engl J Med. 2005 Jan 13; 352(2):185-94. PMID: 15647582.
    View in: PubMed
  222. Gaviani P, Gonzalez RG, Zhu JJ, Batchelor TT, Henson JW. Central neurogenic hyperventilation and lactate production in brainstem glioma. Neurology. 2005 Jan 11; 64(1):166-7. PMID: 15642931.
    View in: PubMed
  223. Grier J, Batchelor T. Metastatic neurologic complications of non-Hodgkin's lymphoma. Curr Oncol Rep. 2005 Jan; 7(1):55-60. PMID: 15610687.
    View in: PubMed
  224. Voloschin AD, Louis DN, Cosgrove GR, Batchelor TT. Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study. Neuro Oncol. 2005 Jan; 7(1):97-100. PMID: 15701287; PMCID: PMC1871619.
  225. Drappatz J, Batchelor T. Neurologic complications of plasma cell disorders. Clin Lymphoma. 2004 Dec; 5(3):163-71. PMID: 15636691.
    View in: PubMed
  226. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 01; 10(17):5643-6. PMID: 15355887.
    View in: PubMed
  227. New PZ, Grossman S, Mikkelsen T, Batchelor T, Phuphanich S, Carson K, Fisher J, Craig M, Cagnoni P. Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1533. PMID: 28015406.
    View in: PubMed
  228. Batchelor T, Grossman S, Carson K, Fisher J. Updated results from NABTT CNS consortium studies in primary CNS lymphoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1519. PMID: 28015360.
    View in: PubMed
  229. Shah G, Kesari S, Xu R, Henson J, Batchelor T, Hochberg F, Oneill A, Levy B, Bradshaw J, Wen PY. Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1523. PMID: 28015429.
    View in: PubMed
  230. DeAngelis L, Batchelor T. Primary CNS lymphoma: is there a role for prophylaxis against lymphomatous meningitis? Expert Rev Neurother. 2004 Jul; 4(4 Suppl):S19-24. PMID: 15853551.
    View in: PubMed
  231. Jeyapalan SA, Batchelor T. Management of Brain Metastases. Curr Treat Options Neurol. 2004 Jul; 6(4):273-284. PMID: 15157405.
    View in: PubMed
  232. He X, Batchelor TT, Grossman S, Supko JG. Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 25; 799(2):281-91. PMID: 14670747.
    View in: PubMed
  233. Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, Lesser GJ, Mikkelsen T, Phuphanich S. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol. 2004 Jan; 6(1):21-7. PMID: 14769136; PMCID: PMC1871974.
  234. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):228-33. PMID: 14734474.
    View in: PubMed
  235. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology. 2003 Sep 09; 61(5):696-8. PMID: 12963767.
    View in: PubMed
  236. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003 Aug 01; 9(8):2940-9. PMID: 12912940.
    View in: PubMed
  237. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003 Jun 15; 21(12):2299-304. PMID: 12805330.
    View in: PubMed
  238. Ferreri AJ, Abrey LE, Blay JY, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol. 2003 Jun 15; 21(12):2407-14. PMID: 12805341.
    View in: PubMed
  239. Ferreri AJ, Batchelor T, Zucca E, Cavalli F, Armitage J. International Collaborative Group against Primary CNS Lymphomas. J Clin Oncol. 2003 Apr 15; 21(8):1649-50. PMID: 12697892.
    View in: PubMed
  240. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7. PMID: 12670911.
    View in: PubMed
  241. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003 Mar 15; 21(6):1044-9. PMID: 12637469.
    View in: PubMed
  242. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003 Mar; 9(3):1063-9. PMID: 12631608.
    View in: PubMed
  243. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003 Feb; 9(2):711-5. PMID: 12576439.
    View in: PubMed
  244. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003 Feb; 21(1):25-66. PMID: 12690644.
    View in: PubMed
  245. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Curr Treat Options Oncol. 2002 Dec; 3(6):525-35. PMID: 12392641.
    View in: PubMed
  246. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002 May; 57(3):231-9. PMID: 12125986.
    View in: PubMed
  247. Batchelor T, Stanley K, Andersen J. Clinical trials in neuro-oncology. Curr Opin Neurol. 2001 Dec; 14(6):689-94. PMID: 11723375.
    View in: PubMed
  248. Batchelor T, Leahy N, Kaufman D. High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. Clin Lymphoma. 2001 Sep; 2(2):116-9; discussion 120-2. PMID: 11707852.
    View in: PubMed
  249. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol. 2001 Jun; 2(6):354-65. PMID: 11905752.
    View in: PubMed
  250. Plotkin SR, Batchelor TT. Advances in the therapy of primary central nervous system lymphoma. Clin Lymphoma. 2001 Mar; 1(4):263-75; discussion 276-7. PMID: 11707839.
    View in: PubMed
  251. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001 Jan; 84(2):157-63. PMID: 11161370; PMCID: PMC2363714.
  252. Ciordia R, Supko J, Gatineau M, Batchelor T. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr Oncol Rep. 2000 Sep; 2(5):445-53. PMID: 11122877.
    View in: PubMed
  253. Batchelor T. Temozolomide for malignant brain tumours. Lancet. 2000 Apr 01; 355(9210):1115-6. PMID: 10791369.
    View in: PubMed
  254. Quiñones-Hinojosa A, Friedlander RM, Boyer PJ, Batchelor TT, Chiocca EA. Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg. 2000 Jan; 92(1):165-9. PMID: 10616097.
    View in: PubMed
  255. Jeyapalan SA, Batchelor TT. Diagnostic evaluation of neurologic metastases. Cancer Invest. 2000; 18(4):381-94. PMID: 10808374.
    View in: PubMed
  256. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999 Oct; 17(10):3110-6. PMID: 10506606.
    View in: PubMed
  257. Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol. 1999 Apr; 17(4):1329. PMID: 10561199.
    View in: PubMed
  258. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999; 4(3):209-24. PMID: 10394589.
    View in: PubMed
  259. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain. 1999 Jan; 122 ( Pt 1):27-39. PMID: 10050892.
    View in: PubMed
  260. Batchelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol. 1998 Nov; 40(2):131-6. PMID: 9892095.
    View in: PubMed
  261. Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients. Neurol Clin. 1998 May; 16(2):449-83. PMID: 9537970.
    View in: PubMed
  262. Batchelor TT, Platten M, Palmer-Toy DE, Hunter GJ, Lev MH, Dalmau J, Hochberg FH. Chorea as a paraneoplastic complication of Hodgkin's disease. J Neurooncol. 1998 Jan; 36(2):185-90. PMID: 9525818.
    View in: PubMed
  263. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997 May; 48(5):1234-8. PMID: 9153449.
    View in: PubMed
  264. Batchelor TT, Krol GS, DeAngelis LM. Neuroimaging abnormalities with hypoglossal nerve palsies. J Neuroimaging. 1997 Apr; 7(2):86-8. PMID: 9128445.
    View in: PubMed
  265. Batchelor TT, Krol GS, DeAngelis LM. Neuroimaging abnormalities with hypoglossal nerve palsies. J Neuroimaging. 1996 Oct; 6(4):240-2. PMID: 8903077.
    View in: PubMed
  266. Batchelor T, DeAngelis LM. Medical management of cerebral metastases. Neurosurg Clin N Am. 1996 Jul; 7(3):435-46. PMID: 8823773.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Batchelor's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_